The Impact of the Nervous System on Arteries and the Heart: The Neuroimmune Cardiovascular Circuit Hypothesis

Cells. 2023 Oct 19;12(20):2485. doi: 10.3390/cells12202485.

Abstract

Three systemic biological systems, i.e., the nervous, the immune, and the cardiovascular systems, form a mutually responsive and forward-acting tissue network to regulate acute and chronic cardiovascular function in health and disease. Two sub-circuits within the cardiovascular system have been described, the artery brain circuit (ABC) and the heart brain circuit (HBC), forming a large cardiovascular brain circuit (CBC). Likewise, the nervous system consists of the peripheral nervous system and the central nervous system with their functional distinct sensory and effector arms. Moreover, the immune system with its constituents, i.e., the innate and the adaptive immune systems, interact with the CBC and the nervous system at multiple levels. As understanding the structure and inner workings of the CBC gains momentum, it becomes evident that further research into the CBC may lead to unprecedented classes of therapies to treat cardiovascular diseases as multiple new biologically active molecules are being discovered that likely affect cardiovascular disease progression. Here, we weigh the merits of integrating these recent observations in cardiovascular neurobiology into previous views of cardiovascular disease pathogeneses. These considerations lead us to propose the Neuroimmune Cardiovascular Circuit Hypothesis.

Keywords: artery; atherosclerosis; brain; heart; neuroimmune interactions.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Arteries
  • Cardiovascular Diseases*
  • Central Nervous System
  • Central Nervous System Depressants* / pharmacology
  • Heart
  • Humans
  • Neuroimmunomodulation

Substances

  • Central Nervous System Depressants

Grants and funding

This work has been supported by Deutsche Forschungsgemeinschaft (DFG): MO 3054/1-1, SFB1123-Z1, and the Corona Foundation grant (S199/10087/2022) to S.K.M.; YI 133/3-5, to C.Y.; HA 1083/15-5; and ERA-CVD (PLAQUEFIGHT) 01KL1808 to A.J.R.H.; DFG Cluster of Excellence SyNergy (EXC 2145 SyNergy 390857198) to C.W.; and Easemedcontrol R & D Gmbh and Co KG to S.K.M, C.Y. and A.J.R.H. The APC was funded by LMU Open Access.